Ment 50 - Canada Peptides

Despite being synthesized in the 1960s, Trestolone acetate remained in obscurity until researchers revisited it in the late 1990s and early 2000s. A pivotal study in 1998 revealed that MENT had ten times the anabolic effect of testosterone and only twice the androgenic activity. This finding opened up possibilities for safer testosterone replacement options and even male hormonal contraception. Schering AG, which had previously worked on other steroid formulations, saw MENT as a viable next-generation hormone therapy, particularly due to its strong activity without DHT conversion.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Ment 50 by Canada Peptides, consult with your doctor or healthcare professional.